v3.26.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Cash flows from operating activities:    
Net income attributable to The Vita Coco Company, Inc. $ 114,942 $ 65,793
Adjustments required to reconcile net income to cash flows from operating activities:    
Depreciation and amortization 2,458 636
Amortization of debt issuance cost 14 11
Increase of provision for credit losses 187 1,300
Unrealized (gain) on derivative instruments (511) (6,275)
Stock-based compensation 11,338 8,123
Impairment loss on Runa assets 0 185
Noncash lease expense 1,242 1,052
Changes in operating assets and liabilities:    
Accounts receivable (42,801) (39,706)
Inventory 33,259 (302)
Prepaid expenses, net supplier advances, and other assets (7,236) 345
Accounts payable, accrued expenses, and other liabilities 39,050 19,907
Net cash provided by operating activities 151,942 51,069
Cash flows from investing activities:    
Cash paid for property and equipment (803) (4,921)
Acquisition of Copra Inc., net of $8,340 cash acquired (139,253) 0
Net cash used in investing activities (140,056) (4,921)
Cash flows from financing activities:    
Proceeds from exercise of stock awards 6,131 2,281
Cash paid on notes payable (3) (8)
Cash paid to acquire treasury stock (62,410) (10,204)
Net cash used in financing activities (56,282) (7,931)
Effects of exchange rate changes on cash and cash equivalents (475) 833
Net (decrease) increase in cash and cash equivalents (44,871) 39,050
Cash, cash equivalents and restricted cash at beginning of the period [1] 198,154 165,933
Cash, cash equivalents and restricted cash at end of period [1] $ 153,283 $ 204,983
[1] Includes $1,281 and $1,264 of restricted cash as of December 31, 2025 and 2024, respectively. Includes $1,288 and $1,278 of restricted cash as of September 30, 2026 and 2025, respectively, reported in other current assets on the condensed consolidated balance sheet.
During the nine months ended September 30, 2026, the Company issued common stock with a fair value of $35,000 and recognized deferred and contingent consideration with a combined fair value of $55,100 in connection with the acquisition of Copra. These transactions are noncash investing and financing activities.